Adenomatous Polyposis Coli Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major adenomatous polyposis coli markets are expected to exhibit a CAGR of 4.1% during 2024-2034.
The adenomatous polyposis coli market has been comprehensively analyzed in IMARC's new report titled "Adenomatous Polyposis Coli Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenomatous polyposis coli (APC) is a hereditary genetic disorder characterized by the formation of numerous polyps in the colon and rectum. These polyps, which are small growths on the inner lining of the gastrointestinal tract, have the potential to turn cancerous over time, leading to an increased risk of colorectal cancer. The symptoms of APC can vary but often include abdominal pain, changes in bowel habits, rectal bleeding, and unintended weight loss. However, in some cases, individuals suffering from the ailment may remain asymptomatic for an extended period, making early diagnosis crucial for effective management. The diagnosis of APC typically involves a combination of medical history assessment, physical examination, and imaging studies, which allow direct visualization of the polyps. Genetic testing is also recommended to identify gene mutations that help to confirm the diagnosis as well as aid in risk assessment and appropriate genetic counseling for patients.
The increasing cases of gene mutations that interfere with the normal function of the protein, resulting in abnormal cell proliferation and the formation of polyps in the colon and rectum, are primarily driving the adenomatous polyposis coli market. In addition to this, the inflating utilization of potent medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), sulindac, and celecoxib, designed to reduce the size and number of polyps, is also creating a positive outlook for the market. Moreover, the widespread adoption of endoscopic procedures like colectomy and prophylactic surgeries, since they are aimed at polyp removal and risk reduction, is further bolstering the market growth. These interventions help in halting disease progression and averting the potential transformation of polyps into malignancies. Apart from this, the rising usage of targeted therapies and immunotherapies that focus on interrupting cellular signals associated with the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of genetic counseling services to enable early detection of APC mutations and encourage informed decision-making for patients and their families is also augmenting the market growth. Furthermore, the escalating application of gene therapy, which works by introducing functional genes to rectify or replace the mutated genome responsible for the condition, is expected to drive the adenomatous polyposis coli market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adenomatous polyposis coli market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenomatous polyposis coli and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenomatous polyposis coli market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adenomatous polyposis coli market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adenomatous polyposis coli market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current adenomatous polyposis coli marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the adenomatous polyposis coli market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adenomatous polyposis coli market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adenomatous polyposis coli market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with adenomatous polyposis coli across the seven major markets?
What is the size of the adenomatous polyposis coli patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adenomatous polyposis coli?
What will be the growth rate of patients across the seven major markets?
Adenomatous Polyposis Coli: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adenomatous polyposis coli drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenomatous polyposis coli market?
What are the key regulatory events related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by status related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by phase related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by route of administration related to the adenomatous polyposis coli market?
The adenomatous polyposis coli market has been comprehensively analyzed in IMARC's new report titled "Adenomatous Polyposis Coli Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenomatous polyposis coli (APC) is a hereditary genetic disorder characterized by the formation of numerous polyps in the colon and rectum. These polyps, which are small growths on the inner lining of the gastrointestinal tract, have the potential to turn cancerous over time, leading to an increased risk of colorectal cancer. The symptoms of APC can vary but often include abdominal pain, changes in bowel habits, rectal bleeding, and unintended weight loss. However, in some cases, individuals suffering from the ailment may remain asymptomatic for an extended period, making early diagnosis crucial for effective management. The diagnosis of APC typically involves a combination of medical history assessment, physical examination, and imaging studies, which allow direct visualization of the polyps. Genetic testing is also recommended to identify gene mutations that help to confirm the diagnosis as well as aid in risk assessment and appropriate genetic counseling for patients.
The increasing cases of gene mutations that interfere with the normal function of the protein, resulting in abnormal cell proliferation and the formation of polyps in the colon and rectum, are primarily driving the adenomatous polyposis coli market. In addition to this, the inflating utilization of potent medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), sulindac, and celecoxib, designed to reduce the size and number of polyps, is also creating a positive outlook for the market. Moreover, the widespread adoption of endoscopic procedures like colectomy and prophylactic surgeries, since they are aimed at polyp removal and risk reduction, is further bolstering the market growth. These interventions help in halting disease progression and averting the potential transformation of polyps into malignancies. Apart from this, the rising usage of targeted therapies and immunotherapies that focus on interrupting cellular signals associated with the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of genetic counseling services to enable early detection of APC mutations and encourage informed decision-making for patients and their families is also augmenting the market growth. Furthermore, the escalating application of gene therapy, which works by introducing functional genes to rectify or replace the mutated genome responsible for the condition, is expected to drive the adenomatous polyposis coli market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adenomatous polyposis coli market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenomatous polyposis coli and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenomatous polyposis coli market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adenomatous polyposis coli market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adenomatous polyposis coli market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current adenomatous polyposis coli marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the adenomatous polyposis coli market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adenomatous polyposis coli market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adenomatous polyposis coli market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of adenomatous polyposis coli by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with adenomatous polyposis coli across the seven major markets?
What is the size of the adenomatous polyposis coli patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adenomatous polyposis coli?
What will be the growth rate of patients across the seven major markets?
Adenomatous Polyposis Coli: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adenomatous polyposis coli drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenomatous polyposis coli market?
What are the key regulatory events related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by status related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by phase related to the adenomatous polyposis coli market?
What is the structure of clinical trial landscape by route of administration related to the adenomatous polyposis coli market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADENOMATOUS POLYPOSIS COLI - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADENOMATOUS POLYPOSIS COLI - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADENOMATOUS POLYPOSIS COLI - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADENOMATOUS POLYPOSIS COLI - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADENOMATOUS POLYPOSIS COLI - UNMET NEEDS
10 ADENOMATOUS POLYPOSIS COLI - KEY ENDPOINTS OF TREATMENT
11 ADENOMATOUS POLYPOSIS COLI - MARKETED PRODUCTS
11.1 List of Adenomatous Polyposis Coli Marketed Drugs Across the Top 7 Markets
11.1.1 Celebrex (Celecoxib) - Astellas Pharma/Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADENOMATOUS POLYPOSIS COLI - PIPELINE DRUGS
12.1 List of Adenomatous Polyposis Coli Pipeline Drugs Across the Top 7 Markets
12.1.1 REC-4881 - Recursion Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Eicosapentaenoic acid free fatty acid - S.L.A. Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 eRapa - Emtora Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADENOMATOUS POLYPOSIS COLI - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADENOMATOUS POLYPOSIS COLI – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADENOMATOUS POLYPOSIS COLI - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adenomatous Polyposis Coli - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adenomatous Polyposis Coli - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adenomatous Polyposis Coli - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adenomatous Polyposis Coli - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adenomatous Polyposis Coli - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adenomatous Polyposis Coli - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adenomatous Polyposis Coli - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adenomatous Polyposis Coli - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
16 ADENOMATOUS POLYPOSIS COLI - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADENOMATOUS POLYPOSIS COLI MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADENOMATOUS POLYPOSIS COLI MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADENOMATOUS POLYPOSIS COLI - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADENOMATOUS POLYPOSIS COLI - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADENOMATOUS POLYPOSIS COLI - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADENOMATOUS POLYPOSIS COLI - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADENOMATOUS POLYPOSIS COLI - UNMET NEEDS
10 ADENOMATOUS POLYPOSIS COLI - KEY ENDPOINTS OF TREATMENT
11 ADENOMATOUS POLYPOSIS COLI - MARKETED PRODUCTS
11.1 List of Adenomatous Polyposis Coli Marketed Drugs Across the Top 7 Markets
11.1.1 Celebrex (Celecoxib) - Astellas Pharma/Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADENOMATOUS POLYPOSIS COLI - PIPELINE DRUGS
12.1 List of Adenomatous Polyposis Coli Pipeline Drugs Across the Top 7 Markets
12.1.1 REC-4881 - Recursion Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Eicosapentaenoic acid free fatty acid - S.L.A. Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 eRapa - Emtora Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADENOMATOUS POLYPOSIS COLI - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADENOMATOUS POLYPOSIS COLI – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADENOMATOUS POLYPOSIS COLI - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adenomatous Polyposis Coli - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adenomatous Polyposis Coli - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adenomatous Polyposis Coli - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adenomatous Polyposis Coli - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adenomatous Polyposis Coli - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adenomatous Polyposis Coli - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adenomatous Polyposis Coli - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adenomatous Polyposis Coli - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adenomatous Polyposis Coli - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adenomatous Polyposis Coli - Access and Reimbursement Overview
16 ADENOMATOUS POLYPOSIS COLI - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADENOMATOUS POLYPOSIS COLI MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADENOMATOUS POLYPOSIS COLI MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
